Compare Super Micro Computer Inc (SMCI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Super Micro Computer Inc vs TG Therapeutics Inc — how do they compare? Super Micro Computer Inc trades at $30 (market cap $15.41B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Super Micro Computer Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Super Micro Computer Inc nearer its low. Which is the better fit depends on your goals.
| SMCI | TGTX | |
|---|---|---|
Market Cap | $15.41B | $8.26B |
Sector | Technology | Health |
52-Week High | $60.71 | $59.06 |
52-Week Low | $20.53 | $26.39 |
Enterprise Value | $22.93B | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Super Micro Computer (SMCI) trades at $23.83, down 1.41% on the day, with technical indicators showing bearish momentum despite recent positive earnings beats. The company reported strong Q1 2026 results with EPS of $0.84 beating expectations of $0.617, while preliminary Q4 guidance indicates significant margin expansion to 15-17% and over $60 billion in new orders. Valuation metrics remain attractive with P/E of 12.54 and P/S of 0.47, though cash flow trends show volatility with 2026 projections indicating operational challenges.
The outlook appears cautiously optimistic with analyst consensus price target of $36.71 representing 54% upside potential, though technical weakness and competitive pressures in AI hardware create near-term headwinds. Key risks include execution on massive order backlog, margin sustainability, and intense competition from Dell and HPE in the AI server market.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Super Micro Computer Inc
Super Micro Computer, Inc., commonly known as Supermicro, is a leading provider of high-performance and high-efficiency server technology and innovation. The company specializes in designing, manufacturing, and selling advanced server, storage, and networking solutions, primarily for data centers, cloud computing, artificial intelligence, and 5G/Edge computing markets. SMCI's modular architecture allows for the rapid delivery of customized and purpose-built solutions, making it a key player in the enterprise computing and specialized AI infrastructure space.
Read more on SMCI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
